Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

EXPERT REVIEW OF VACCINES

TAYLOR & FRANCIS LTD

1. Pfizer Japan Inc., Tokyo, Japan